Journal of Neurology

, Volume 256, Issue 2, pp 268–270

IVIG trials in MS. Is albumin a placebo?

  • O. R. Hommes
  • J. Haas
  • P. Soelberg-Sorenson
  • M. Friedrichs
LETTER TO THE EDITORS

Abbreviations

BBB

Blood Brain Barrier

CIS

Clinical Isolated Syndrome

EAE

Experimental Allergic Encephalomyelitis

EDSS

Expanded Disability Status Scale

IFB

Interferon-beta

IVIG

Intravenous Immunoglobulin

MS

Multiple Sclerosis

PP

Primary Progressive MS

RR

Relapsing Remitting MS

RDB

Randomized Double-Blind Placebo Controlled

SDV

Saline or Dextrose or Vehicle

SP

Secondary Progressive MS

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sørensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9(69):557–563PubMedCrossRefGoogle Scholar
  2. 2.
    Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Soelberg Sørensen P, Maas-Enriquez M, Sommerauer B, Hanna K; for the PRIVIG Study Group and the UBC MS/ MRI Research Group (2008) Intravenous immunoglobulin in relapsing-remitting multiple sclerosis. A dose finding trial. Neurology 71(4):265–271PubMedCrossRefGoogle Scholar
  3. 3.
    Pöhlau D, Przuntek H, Sailer M, Bethke F, Koehler J, König N, Heesen C, Späth P, Andresen I (2007) Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicenter study. Mult Scler 13:1107–1117PubMedCrossRefGoogle Scholar
  4. 4.
    Sørensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, Kirsmeier H, Larsen VA, Lee ML (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50(5):1273–1281PubMedGoogle Scholar
  5. 5.
    Fazekas F., Deisenhammer F, Strasser Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group [see comments]. Lancet 349(9052):589–593PubMedCrossRefGoogle Scholar
  6. 6.
    Achiron A, Gabbay U, Gilad R, Hassin B S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova PI (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50(2):398–402PubMedGoogle Scholar
  7. 7.
    Lewanska M, Zajdal MS, Selmaj K (2002) No difference in efficacy of two different doses of intravenous immunoglobulins in MS: Clinical and MRI assessment. Blackwell Publishing. Eur J Neurol (In press)Google Scholar
  8. 8.
    Koçer B, Yildirim-Gürel S, Tah E, Irkeç C, Isik S (2004) The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G. Neuroradiology 46:287–290PubMedCrossRefGoogle Scholar
  9. 9.
    Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, Lavie M, Gurevich M, Dolev M, Magalashvili D, Barak Y (2004) “Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, doubleblind, placebo-controlled trial”. Arch Neurol 61(10):1515–1520PubMedCrossRefGoogle Scholar
  10. 10.
    Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S (2000) “Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis”. J Neurol Neurosurg Psychiatry 68(1):89–92PubMedCrossRefGoogle Scholar
  11. 11.
    Rewald E, Saito N, Kohgo Y (1995) Is intravenous albumin a placebo? Lancet 346:1497PubMedCrossRefGoogle Scholar
  12. 12.
    Hommes OR, Sørensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, Pozzilli C, O’Connor P (2004) “Intravenous Immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial”. Lancet 364(9440):1149–1156PubMedCrossRefGoogle Scholar
  13. 13.
    Noseworthy JH, O’Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, Windebank AJ, Whisnant JP, Stolp-Smith KA, Harper CM, Jr, Low PA, Romme LJ, Johnson M, An KN, Rodriguez M (2000) “IV immunoglobulin does not reverse established weakness in MS”. Neurology 55(8):1135–1143PubMedGoogle Scholar
  14. 14.
    Noseworthy JH, O’Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, Sneve D, Cross SA, Leavitt JA, Auger RG, Weinshenker BG, Dodick DW, Wingerchuk DM, Rodriguez M (2001) “A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis”. Neurology 56(11):1514–1522PubMedGoogle Scholar
  15. 15.
    Sørensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M (2004) “IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS”. Neurology 63(11):2028–2033PubMedGoogle Scholar
  16. 16.
    Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, Lenderink AW (2004) “A randomized, double- blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS”. Mult Scler 10(1):89–91PubMedCrossRefGoogle Scholar
  17. 17.
    Roed HG, Langkilde A, Sellebjerg F, Lauritzen M, Bang P, Morup A, Frederiksen JL (2005) “A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis”. Neurology 64(5):804–810PubMedGoogle Scholar
  18. 18.
    Belayev L, Saul I, Busto R, Danielyan A, Vigdorchick L, Khoutorova, Ginsberg M (2005) ”Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat. Stroke 36:326–331PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2009

Authors and Affiliations

  • O. R. Hommes
    • 1
  • J. Haas
    • 3
  • P. Soelberg-Sorenson
    • 2
  • M. Friedrichs
    • 1
  1. 1.European Charcot FoundationMolenhoekThe Netherlands
  2. 2.Danish Multiple Sclerosis Research CentreRigshospitaletCopenhagenDenmark
  3. 3.Abteilung für NeurologieJüdisches Krankenhaus BerlinBerlinGermany

Personalised recommendations